Navigation Links
Medarex Announces Ipilimumab Program Continues to Move Forward
Date:4/3/2008

ce or presence of CTLA- 4 can augment or suppress the immune system's T-cell response in fighting disease. Ipilimumab is designed to block the activity of CTLA-4, thereby sustaining an active immune response in its attack on cancer cells.

Comprehensive Clinical Trial Program for Ipilimumab

Ipilimumab is being developed through a joint partnership between Bristol- Myers Squibb and Medarex. Based on nonclinical and clinical studies showing that antibody blockade of CTLA-4 plays an important role in sustaining an active immune response to fight cancer, Bristol-Myers Squibb and Medarex are pursuing a broad clinical development program with ipilimumab evaluating its potential use in advanced metastatic melanoma, as well as prostate, lung, pancreatic, bladder, breast, lymphoma and leukemia cancers. More than 2,000 patients have been treated with ipilimumab as a monotherapy or in combination with other agents in clinical trials.

For further information about ipilimumab clinical trials, please visit http://www.clinicaltrials.gov.

About Advanced Melanoma

Melanoma is a form of skin cancer characterized by the uncontrolled growth of pigment-producing cells (melanocytes) located in the skin. As with many cancers, it is more difficult to treat once the disease has spread beyond the skin to other parts of the body by way of the bloodstream or the lymphatic system (metastatic disease). Melanoma accounts for about three percent of skin cancer cases, but it causes most skin cancer deaths. The American Cancer Society estimates that in 2007 there will be 59,940 new cases of melanoma in the U.S., and about 8,110 people will die of this disease.

About Medarex

Medarex is a biopharmaceutical company focused on the discovery, development and potential commercialization of fully human antibody-based therapeutics to treat life-threatening and debilitating diseases, including cancer, inf
'/>"/>

SOURCE Medarex, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Medarex Announces Allowance of Investigational New Drug Applications for Wholly Owned Fully Human Anti-CD19 Antibody, MDX-1342
2. Medarex to Receive Milestone Payment from Amgen
3. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
4. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
5. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
6. ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer
7. DOV Pharmaceutical, Inc. Announces Successful Phase Ib Results for DOV 21,947
8. Phosphagenics Announces Positive Phase 1b Transdermal Insulin Clinical Trial Results
9. Xenomics Announces Implementation of its First Diagnostic Test for Acute Myeloid Leukemia Into Clinical Practice
10. Emisphere Technologies, Inc. Announces 2007 Second Quarter Financial Results
11. Amicus Therapeutics Announces Second Quarter 2007 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/30/2014)... NOTTINGHAM, United Kingdom , Oct. 30, 2014 /PRNewswire/ ... Inc., (Nasdaq: CBRX ) and ... assist drug developers with improved efficiency during clinical development ... San Diego next week. This ... enabling technologies platform, which it launched earlier this month. ...
(Date:10/30/2014)... , Oct. 30, 2014   BioLife Solutions ... developer, manufacturer and marketer of proprietary clinical grade ... and precision thermal shipping products for cells ... quarter 2014 financial results will be released on Thursday, ... a conference call and live webcast at 1:30 p.m. ...
(Date:10/30/2014)...   Auxilium Pharmaceuticals , Inc. (NASDAQ: ... company, today announced financial results for the third ... important corporate, commercial, regulatory and clinical development updates ... very pleased with the continued momentum and strong ... portfolio this quarter, especially the XIAFLEX franchise, which ...
Breaking Medicine Technology:Molecular Profiles To Launch US Strategic Alliance At AAPS 2Molecular Profiles To Launch US Strategic Alliance At AAPS 3BioLife Solutions to Report Financial Results for Third Quarter 2014 and Provide Business Update on November 6, 2014 2Auxilium Pharmaceuticals, Inc. Announces Third Quarter 2014 Financial Results 2Auxilium Pharmaceuticals, Inc. Announces Third Quarter 2014 Financial Results 3Auxilium Pharmaceuticals, Inc. Announces Third Quarter 2014 Financial Results 4Auxilium Pharmaceuticals, Inc. Announces Third Quarter 2014 Financial Results 5Auxilium Pharmaceuticals, Inc. Announces Third Quarter 2014 Financial Results 6Auxilium Pharmaceuticals, Inc. Announces Third Quarter 2014 Financial Results 7Auxilium Pharmaceuticals, Inc. Announces Third Quarter 2014 Financial Results 8Auxilium Pharmaceuticals, Inc. Announces Third Quarter 2014 Financial Results 9Auxilium Pharmaceuticals, Inc. Announces Third Quarter 2014 Financial Results 10Auxilium Pharmaceuticals, Inc. Announces Third Quarter 2014 Financial Results 11Auxilium Pharmaceuticals, Inc. Announces Third Quarter 2014 Financial Results 12Auxilium Pharmaceuticals, Inc. Announces Third Quarter 2014 Financial Results 13Auxilium Pharmaceuticals, Inc. Announces Third Quarter 2014 Financial Results 14Auxilium Pharmaceuticals, Inc. Announces Third Quarter 2014 Financial Results 15Auxilium Pharmaceuticals, Inc. Announces Third Quarter 2014 Financial Results 16Auxilium Pharmaceuticals, Inc. Announces Third Quarter 2014 Financial Results 17Auxilium Pharmaceuticals, Inc. Announces Third Quarter 2014 Financial Results 18Auxilium Pharmaceuticals, Inc. Announces Third Quarter 2014 Financial Results 19Auxilium Pharmaceuticals, Inc. Announces Third Quarter 2014 Financial Results 20Auxilium Pharmaceuticals, Inc. Announces Third Quarter 2014 Financial Results 21Auxilium Pharmaceuticals, Inc. Announces Third Quarter 2014 Financial Results 22
... and Progressive Form of Inflammatory Spinal Arthritis Receiving Monthly Golimumab ... ... BOSTON, Nov. 7 More than half of patients receiving,monthly ... experienced significant and sustained improvements in the signs and,symptoms of active ...
... of Trial Volunteers Must Remain Paramount Concern, SEATTLE, ... the following statement today from Executive,Director Mitchell Warren in ... AIDS vaccine study by Merck & Co., the US ... HIV Vaccine Trials Network,(HVTN) at a public forum at ...
Cached Medicine Technology:New Anti-TNF Golimumab Significantly Reduced Signs and Symptoms of Ankylosing Spondylitis According to Phase 3 Study Findings 2New Anti-TNF Golimumab Significantly Reduced Signs and Symptoms of Ankylosing Spondylitis According to Phase 3 Study Findings 3New Anti-TNF Golimumab Significantly Reduced Signs and Symptoms of Ankylosing Spondylitis According to Phase 3 Study Findings 4New Anti-TNF Golimumab Significantly Reduced Signs and Symptoms of Ankylosing Spondylitis According to Phase 3 Study Findings 5New Anti-TNF Golimumab Significantly Reduced Signs and Symptoms of Ankylosing Spondylitis According to Phase 3 Study Findings 6New Anti-TNF Golimumab Significantly Reduced Signs and Symptoms of Ankylosing Spondylitis According to Phase 3 Study Findings 7AIDS Vaccine Advocacy Coalition Calls for AIDS Vaccine Field to Work Together to Analyze STEP Study Data and Determine Best Course to Move Forward 2AIDS Vaccine Advocacy Coalition Calls for AIDS Vaccine Field to Work Together to Analyze STEP Study Data and Determine Best Course to Move Forward 3
(Date:10/31/2014)... Steven Reinberg HealthDay Reporter THURSDAY, ... increase slightly the risk of broken bones and injured joints, a ... found that among 7 percent of people who had an eczema ... joint injury and 0.6 percent had an injury that caused a ... with the skin condition had more than double the risk of ...
(Date:10/30/2014)... October 30, 2014—(BRONX, NY)—Investigators at Albert Einstein ... and Montefiore Medical Center will present their ... America,s (GSA) 67th Annual Scientific Meeting. Topics include ... survival, risk factors for cognitive impairment and the ... place November 5-9, 2014 in Washington, D.C., "Einstein-Montefiore ...
(Date:10/30/2014)... – You have to be at least 2 years ... younger babies, no official U.S. guidance exists other than ... mothers exclusively breastfeed for at least the first six ... , That,s the question that motivated researchers at ... Sciences to study the eating patterns of American infants ...
(Date:10/30/2014)... October 30, 2014 Nutrition Leaders, a ... weight loss aids, and more, is currently hosting a ... is already underway, is open to U.S. residents age ... December 15, 2014. One lucky winner will then be ... a $100 gift card to NutritionLeaders.com. , Nutrition Leaders’ ...
(Date:10/30/2014)... 30, 2014 Don Allred Insurance, a ... insurance plans for North Carolina residents, is excited to ... Burlington’s Holly Hill Mall. The new branch has been ... helping customers through all facets of the insurance selection ... Insurance spokesman Scott Allred couldn’t be happier with the ...
Breaking Medicine News(10 mins):Health News:Eczema Tied to Bone Fracture Risk in Study 2Health News:Einstein-Montefiore investigators present aging research at Gerontological Society of America's Annual Scientific Meeting 2Health News:Einstein-Montefiore investigators present aging research at Gerontological Society of America's Annual Scientific Meeting 3Health News:Einstein-Montefiore investigators present aging research at Gerontological Society of America's Annual Scientific Meeting 4Health News:What do American babies eat? A lot depends on Mom's socioeconomic background 2Health News:What do American babies eat? A lot depends on Mom's socioeconomic background 3Health News:Nutrition Leaders Announces Gift Card Sweepstakes 2Health News:Allred Insurance Satellite Office Grand Opening 2
... with Exciting New Line ... of Toys, ALPHARETTA, ... Bright Starts(TM) introduces its newest collection of,toys designed to delight babies with endless ... as he or,she explores a wide range of toys, from plush pals to ...
... ORANGE, N.J., July 8 The Henry H. ... people with,disabilities, announced today two key personnel changes ... A. DeLisa, M.D., current President of Kessler,Medical Rehabilitation ... while John DeLuca, Ph.D. will become the Vice ...
... Data, Structured Reporting, Scheduling and ... OAKLAND, Calif., July 8 The University of ... suite of IT,applications to equip their CV service lines ... to integrate disparate,systems, streamline workflow, improve quality, and help ...
... Improve Quality of Patient Data System, CAMBRIDGE, ... plc (LSE: AU. or AU.L), a global leader ... Servicio,Extremeno de Salud (SES), a provider of public ... Extremadura region of Spain, has selected,Autonomy,s Meaning-based Computing ...
... GRAS announces two new important features. A brand new version ... on-the-fly photometric analysis and report generation. The second item, is a ... imaging for themselves using the G13 telescope, located in Australia (more ... ...
... MedRetreat Offers 5 Steps to Help International Medical Providers Partner With Only ... ... 8, 2008 -- As interest in medical tourism heats up ... up to cash in on the emerging industry. But international hospitals should ...
Cached Medicine News:Health News:Bright Starts(TM) Adds New Twist to Old Favorites 2Health News:Bright Starts(TM) Adds New Twist to Old Favorites 3Health News:The Henry H. Kessler Foundation Appoints New Vice President for Research and Strengthens Relationship With Current Research Luminary 2Health News:Building a Fully Integrated Cardiovascular Imaging and Information System Webinar 2Health News:Spanish Health Service Provider Selects Autonomy to Deliver Innovation Within Healthcare 2Health News:Spanish Health Service Provider Selects Autonomy to Deliver Innovation Within Healthcare 3Health News:GRAS Proudly Announces Photometrica Version 2.0. Hailed as a Brilliant Solution for More Productive Astronomical Research by Those Engaged in Photometry Using the Global-Rent-a-scope Telescope Systems 2Health News:GRAS Proudly Announces Photometrica Version 2.0. Hailed as a Brilliant Solution for More Productive Astronomical Research by Those Engaged in Photometry Using the Global-Rent-a-scope Telescope Systems 3Health News:An American Appeal to Overseas Hospitals 2
... rotary retracting, self-lubricating design and has a heavy ... construction makes it accurate and incredibly reliable. ,The ... lateral motion is controlled and allows no slop ... lesser designs which can result in 'chatter' and ...
... The new SureCut M3500 Radial Microtome has ... is marvelous, and a range of functions and ... users. Based on years of experience and ... innovative design the SureCut M3500 Microtome will be ...
This is an economical (portable) microtome designed for fast and accurate sectioning. The specimen rise is automatic and accurate with each handle movement. Section thickness from 5 to 40 microns. ...
Honing compound for knife sharpening, 6 grams net...
Medicine Products: